Trial Profile
A phase II, multicentre, double-blind, randomised, dose range finding placebo controlled study of rifaximin-EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms Retic-03
- Sponsors Alfa Wassermann SpA
- 28 Jun 2012 Planned number of patients changed from 410 to 424 as reported by European Clinical Trials Database.
- 06 Dec 2011 Results published in the Gastroenterology.
- 06 Dec 2011 Primary endpoint 'Remission-rate' has been met.